TC BioPharm Holdings PLC (PK) TCBPY

Alternate Symbol(s): TCBWF

Healthcare Biotechnology

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, develops immunotherapy products based on its allogeneic gamma delta T cell platform in the United States. Its product pipeline comprises OmnImmune (TCB002), an allogeneic unmodified gamma-delta T cell therapy product which is in phase 2/3 clinical trial for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections, as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.

PINL:TCBPY - Post by User

TC BioPharm Holdings PLC (PK)

<< Previous

Bullboard Posts

(950)
•••

Post by Iseneschalon Mar 21, 2025 10:53am

24 Views

Post# 36503696

TCBP....Another one "bites the dust"

TCBP Announces Transition from Nasdaq to OTC Markets

2025-03-21 07:45 ET - News Release

TCBP Announces Transition from Nasdaq to OTC Markets

PR Newswire

EDINBURGH, Scotland, March 21, 2025

EDINBURGH, Scotland, March 21, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company"), (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that on March 20, 2025, it received notice that the Nasdaq Hearings Panel had determined to delist the Company's securities from The Nasdaq Stock Market LLC ("Nasdaq") due to the Company's failure to comply with Rule 5550(a)(2) of Nasdaq's Listing Rules. The Rule requires listed securities to maintain a minimum bid price of $1.00 per share. Management is currently working on an appeal with Nasdaq.